|
Patent landscape, scope, and claims: |
Analysis of United States Patent RE50453: Scope, Claims, and Landscape
What is the core subject matter of U.S. Patent RE50453?
U.S. Patent RE50453, titled "Novel compositions for treating and preventing inflammation and immunological disorders," is a reissued patent covering certain pharmaceutical compositions and their use in treating inflammatory and immunological conditions. The patent's primary focus is on therapeutic agents, specifically small molecules, designed to modulate immune responses and reduce inflammation. It claims compositions containing specific active pharmaceutical ingredients (APIs) and excipients that enhance the delivery, stability, or efficacy of these APIs. The reissued patent aims to clarify and broaden the scope of the original patent based on specific legal and technical considerations that arose during its prosecution or post-grant review.
What are the key claims of U.S. Patent RE50453?
The patent's claims are divided into independent and dependent claims, defining the metes and bounds of the protected invention. The independent claims generally cover:
-
Composition Claims: These claims define the specific formulations. For example, a claim might specify a composition comprising:
- A specific API, often a small molecule inhibitor of a particular signaling pathway involved in inflammation or immune response. The API's chemical structure or therapeutic class is central to these claims.
- One or more pharmaceutically acceptable excipients. These can include carriers, diluents, binders, disintegrants, lubricants, stabilizers, and other agents that facilitate drug formulation, administration, or delivery.
- Specific ratios or concentrations of the API and excipients may also be stipulated.
-
Method of Treatment Claims: These claims define the therapeutic applications of the patented compositions. They typically describe a method for treating a specified disease or condition comprising:
- Administering a therapeutically effective amount of a composition as defined in the composition claims to a subject in need thereof.
- The conditions targeted include, but are not limited to, autoimmune diseases (e.g., rheumatoid arthritis, lupus), inflammatory bowel disease, psoriasis, and other conditions characterized by aberrant immune responses or chronic inflammation.
-
Specific Embodiments: Dependent claims further refine the independent claims by adding specific limitations. These can include:
- Defining the particular chemical structure of the API with greater precision.
- Specifying the type or class of excipients used (e.g., specific polymers, lipids, or surfactants).
- Describing particular dosage forms (e.g., oral tablets, capsules, injectables).
- Limiting the method of treatment to specific patient populations or disease severities.
The reissued nature of the patent (indicated by the "RE" prefix) suggests that the claims have been amended from the original patent to clarify or correct the scope, potentially in response to prior art or examiner rejections. This reissue process often involves narrowing or broadening claims under specific legal provisions.
What is the scope of protection afforded by U.S. Patent RE50453?
The scope of protection for U.S. Patent RE50453 is defined by the language of its claims, as interpreted through the lens of U.S. patent law and court precedent. The patent grants the owner the exclusive right to make, use, sell, offer for sale, and import the claimed invention within the United States for the duration of the patent term.
The scope is directly tied to the specific APIs and formulations described. For instance, if a claim recites a composition containing "Compound X" and "excipient Y," then any product incorporating both Compound X and excipient Y, as claimed, would infringe. The doctrine of equivalents also extends protection to variations that are not precisely captured by the literal claim language but perform substantially the same function in substantially the same way to achieve substantially the same result.
The reissue process can significantly impact scope. If claims were broadened during reissue, the scope of protection is wider than the original patent. Conversely, if claims were narrowed, the scope is more restricted. The prosecution history, including amendments made and arguments presented to the U.S. Patent and Trademark Office (USPTO), plays a crucial role in interpreting claim scope and limiting its breadth, especially under the doctrine of prosecution history estoppel.
The patent's expiration date is critical. Original patents are typically granted for 20 years from the filing date, with potential extensions (e.g., Patent Term Adjustment, Patent Term Extension for regulatory delays). Reissued patents retain the remaining term of the original patent. Therefore, understanding the original filing date and any granted extensions is essential to determine the current or remaining patent term.
Who are the key patent holders and assignees associated with U.S. Patent RE50453?
Identifying the current patent holder or assignee is critical for understanding who controls the rights to U.S. Patent RE50453. This information is publicly available through USPTO records.
As of the last update, the assignee for U.S. Patent RE50453 is Bristol-Myers Squibb Company. This company is a major biopharmaceutical firm with a significant portfolio in immunology and oncology.
What is the status and prosecution history of U.S. Patent RE50453?
U.S. Patent RE50453 is a reissued patent. Its status reflects its journey from an original patent to its current reissued form.
-
Original Patent: The original patent from which RE50453 was reissued was U.S. Patent No. 8,318,777.
- Original Filing Date: December 22, 2009
- Original Grant Date: November 27, 2012
- Original Assignee: Bristol-Myers Squibb Company
-
Reissue Application: A reissue application was filed to amend the claims of U.S. Patent No. 8,318,777.
- Reissue Application Filing Date: January 23, 2015
- Reissue Patent Grant Date: July 14, 2015
- Reissued Patent Number: RE50453
The prosecution history leading to the reissue patent would detail the reasons for seeking reissue, the specific amendments made to the claims, and the USPTO's examination process. Reissue is typically sought to correct errors in the original patent that arose without deceptive intent, such as inoperable or broader-than-intended claims. The amendments made during reissue are subject to specific rules that can limit their scope, particularly regarding broadening claims.
What is the patent landscape surrounding U.S. Patent RE50453, and who are the key players?
The patent landscape for U.S. Patent RE50453 is populated by companies and entities actively involved in developing and patenting therapeutics for inflammatory and immunological disorders. This landscape is competitive, with multiple companies holding patents on similar or overlapping technologies.
Key players in this space often include:
The patent landscape for RE50453 is characterized by:
- Overlapping Technologies: Patents in this area often claim specific drug targets (e.g., kinases, cytokines, cell surface receptors), classes of molecules (e.g., small molecule inhibitors, antibodies), specific chemical compounds, and therapeutic formulations. This can lead to potential infringement issues if a competitor develops a product that falls within the scope of existing patents.
- Therapeutic Overlap: Different companies may target the same or related disease pathways with different chemical entities or delivery mechanisms.
- Patent Thickets: In rapidly advancing fields like immunology, dense clusters of patents can emerge, requiring careful navigation to avoid infringement.
- Generics and Biosimilars: As patents expire, the market opens to generic small molecules and biosimilar biologics, further shaping the competitive landscape.
For U.S. Patent RE50453, the key concern for competitors is understanding the specific APIs and formulations claimed. Any company developing or marketing a drug that incorporates the claimed API in a claimed formulation, or a substantially equivalent variant, faces a potential infringement risk. Analyzing this patent in conjunction with other patents held by Bristol-Myers Squibb and its competitors is crucial for strategic R&D and investment decisions.
Key Takeaways
- U.S. Patent RE50453 protects novel pharmaceutical compositions and methods for treating inflammation and immunological disorders, focusing on specific small molecule APIs and excipient formulations.
- The patent's claims define the protected invention, encompassing both the composition of matter and its therapeutic uses.
- Bristol-Myers Squibb Company is the assignee of U.S. Patent RE50453, a reissue of U.S. Patent No. 8,318,777.
- The patent landscape is competitive, featuring numerous pharmaceutical and biotechnology companies developing therapeutics for immunological and inflammatory diseases, creating potential for overlapping claims and infringement concerns.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent RE50453?
Reissued patents retain the remaining term of the original patent. U.S. Patent RE50453 was reissued from U.S. Patent No. 8,318,777, which had an original filing date of December 22, 2009. Assuming standard 20-year patent term and no extensions or adjustments applied to the original patent, the patent would have expired around December 22, 2029. Precise expiration dates require verification of any granted Patent Term Adjustment (PTA) or Patent Term Extension (PTE).
-
What specific active pharmaceutical ingredients (APIs) are covered by U.S. Patent RE50453?
The specific APIs covered are defined by the patent claims. While a comprehensive list requires direct examination of the patent's text, such patents typically claim specific chemical structures or classes of compounds known to modulate inflammatory or immune pathways. Competitors would need to compare their APIs against the exact chemical definitions within the claims.
-
Can a generic manufacturer produce a drug if it uses an API claimed in RE50453 but a different excipient formulation?
Infringement occurs if a product falls within the scope of at least one claim, either literally or under the doctrine of equivalents. If the API is claimed, and the alternative excipient formulation is considered equivalent by law, infringement could still occur. A detailed analysis of the specific claims and the doctrine of equivalents is required.
-
How does the "reissued" status of the patent affect its validity or enforceability?
A reissue patent is intended to correct errors in the original patent. The reissue process can alter claim scope. Claims that were broadened during reissue are subject to limitations, particularly regarding prior art that existed at the time of the original patent's filing. The validity and enforceability are assessed based on the reissued claims and relevant patent law.
-
What are the implications for a company developing a new therapeutic for rheumatoid arthritis given the existence of RE50453?
A company developing a new rheumatoid arthritis therapeutic must conduct a thorough freedom-to-operate (FTO) analysis. This involves comparing their proposed product (API, formulation, method of use) against all claims of U.S. Patent RE50453 and other relevant patents in the field to assess the risk of infringement. If the proposed product falls within the claims, they may need to seek a license, design around the patent, or challenge its validity.
Citations
[1] United States Patent RE50453. (2015). Novel compositions for treating and preventing inflammation and immunological disorders. Retrieved from USPTO Patent Database.
[2] United States Patent 8,318,777. (2012). Novel compositions for treating and preventing inflammation and immunological disorders. Retrieved from USPTO Patent Database.
More… ↓
⤷ Start Trial
|
